Jump to content

Fasoracetam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 05:56, 3 June 2017 (Undid revision 783566166 by Buddhafinder (talk) we do not give this kind of weight to primary sources. giving EW warning). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fasoracetam
Names
IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
Other names
(5R)-5-oxo-D-prolinepiperidinamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 checkY
    Key: GOWRRBABHQUJMX-MRVPVSSYSA-N checkY
  • InChI=1/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
    Key: GOWRRBABHQUJMX-MRVPVSSYBL
  • O=C(N1CCCCC1)[C@@H]2NC(=O)CC2
Properties
C10H16N2O2
Molar mass 196.250 g·mol−1
Pharmacology
Oral
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate)[1] is a research chemical of the racetam family.[2] It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder.[3]

In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity.[4] In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist[5] and upregulated production of GABAB receptors after repeat dosing.[6]

References

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
  3. ^ "Drug Profile Fasoracetam".
  4. ^ Oka, M; Itoh, Y; Tatsumi, S; Ma, FH; Ukai, Y; Yoshikuni, Y; Kimura, K. "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture". Naunyn Schmiedebergs Arch Pharmacol. 356: 189–96. doi:10.1007/pl00005040. PMID 9272724..
  5. ^ Ogasawara, T; Itoh, Y; Tamura, M; Mushiroi, T; Ukai, Y; Kise, M; Kimura, K. "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer". Pharmacol Biochem Behav. 64: 41–52. doi:10.1016/s0091-3057(99)00108-2. PMID 10494996.
  6. ^ Shimidzu, T; Itoh, Y; Oka, M; Ishima, T; Ukai, Y; Yoshikuni, Y; Kimura, K. "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment". Eur J Pharmacol. 338: 225–32. doi:10.1016/s0014-2999(97)81925-5. PMID 9424016.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Fasoracetam&oldid=783571765"